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Abstract Abuse of amphetamine derivatives such as 3,4-
methylenedioxymethamphetamine (MDMA) and 3,4-meth-
ylenedioxyamphetamine (MDA) is an important issue in
current forensic practice and fatalities are not infrequent.
Therefore, we investigated an immunohistochemical method
to detect the amphetamine analogues MDMA and MDA
in human tissues. For the staining procedure, the Catal-
ysed Signal Amplification (CSA) method using peroxi-
dase (HRP) provided by Dako® and specific monoclonal
antibodies were used. Appropriate controls for validation
of the technique were included. The distribution of these
designer drugs was studied in various brain regions in-
cluding the four lobes, the basal ganglia, hypothalamus,
hippocampus, corpus callosum, medulla oblongata, pons,
cerebellar vermis and, additionally, in the pituitary gland.
A distinct positive reaction was observed in all cortical
brain regions and the neurons of the basal ganglia, the hy-
pothalamus, the hippocampus and the cerebellar vermis
but in the brainstem, relatively weak staining of neurons
was seen. The reaction presented as a mainly diffuse cyto-
plasmic staining of the perikaryon of the neurons, and of-
ten axons and dendrites were also visualised. In addition,
the immunoreactivity was present in the white matter. In
the pituitary gland, however, distinct immunopositive cells
were observed, with a prominent heterogeneity. The im-
munohistochemical findings were supported by the toxi-
cological data. This immunostaining technique can be
used as evidence of intake or even poisoning with MDMA
and/or MDA and can be an interesting tool in forensic
practice when the usual samples for toxicological analysis
are not available. Furthermore, this method can be used to
investigate the distribution of these substances in the hu-
man body.
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Introduction
Abuse of amphetamine and its derivatives is an important
problem in current forensic practice. Moreover fatal and
nearly fatal cases of intoxication are not infrequent [1].
The post-mortem distribution has barely been explored
for amphetamine analogues, except for some case reports
[2, 3, 4, 5, 6] and animal experiments considering this as-
pect for amphetamine or its analogues are scarce [7, 8, 9].
Immunological methods are routinely used for detec-
tion of illegal drugs in clinical and forensic toxicology,
mainly in urine screening tests. However, the principle of
antigen-antibody recognition can also be applied in histo-
logical specimens (immunohistochemistry), allowing de-
tection of drugs in tissue sections. Immunofluorescence
procedures have previously been applied successfully in
animal experiments e.g. detection of morphine in rat tis-
sues [10], demonstration of tetrahydrocannabinol [11] and
phenobarbital [12] in mice tissues. Immunohistochemical
demonstration of morphine and methadone in brain sec-
tions of overdose victims has recently been published [13,
14] and insulin was demonstrated at injection sites by
means of immunohistochemistry [15, 16, 17].
Part of the behavioural, psychotomimetic and neuro-
chemical effects of MDMA (e.g. increase of body temper-
ature, mood alterations, anxiolytic-like effects) may be
explained by the effect on the serotonergic system [18,
19]. Interaction of MDMA with post-synaptic as well as
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pre-synaptic 5-hydroxytryptamine (5-HT, serotonin) re-
cognition sites is postulated [18]. In animal studies, high
affinity of MDMA for 5-HT2 and 5-HT1A serotonin recep-
tors [18] as well as for 5-HT uptake sites was proven [20].
The neurotoxicity of MDMA on 5-HT neurons was also
investigated in humans and subtle, but significant cogni-
tive deficits were noticed [21].
At present, immunohistochemical methods are used to
investigate the biological effects of MDMA, for example,
to demonstrate reductions in 5-HT axon density in rats
and monkeys [22] or rhabdomyolysis [4, 23]. Ishiyama et
al. were able to demonstrate methamphetamine in mice
tissues [24]. To the best of our knowledge, the ampheta-
mine derivatives 3,4-methylenedioxyamphetamine (MDA)
and 3,4-methylenedioxymethamphetamine (MDMA, “ec-
stasy”) have not yet been demonstrated in human tissues.
In this study, we applied the CSA immunostaining
method—known to be the most sensitive method at pre-
sent—for the microscopical immunodetection of MDMA
and MDA. In particular, the distribution of MDMA and
MDA in slides of the human brain and the pituitary gland
of two fatal intoxications was investigated and correlated
with the toxicological findings.
Case histories
Case 1
A 23-year-old man was found dead, sitting on a chair in a
bar. Upon examination, 28 h after death, the body was 186
cm in length and weighed about 100 kg. No conspicuous
lesions or injection sites were noticed. At autopsy, both
lungs weighed 1,620 g and severe pulmonary congestion
and oedema, numerous Tardieu spots on the pleurae and
the pericardium were noticed. The heart weighed 405 g
and a persistence of the left vena cava superior was found.
The brain weighed 1,545 g and congestion and oedema
were confirmed by histological examination. The macro-
scopical and microscopical findings were consistent with
an acute to subacute cardiopulmonary failure as the mech-
anism of death.
MDMA and MDA concentrations were determined in
femoral blood and brain using a HPLC (high pressure liq-
uid chromatography) procedure with fluorescence detec-
tion [5, 25]. For additional confirmation, a fully quantita-
tive LC-MS (liquid chromatography-mass spectrometry)
assay was used for the determination of all specimens.
Cocaine, benzoylecgonine, cocaethylene, ecgonine methyl-
ester, amphetamine, MDMA, MDEA (3,4-methylenedioxy-
ethylamphetamine) and MDA were detected using chro-
matographic analysis: HPLC-DAD (HPLC with diode ar-
ray detection), LC-MS, GC-NPD (gas chromatography with
nitrogen-phosphorus detection) and GC-MS of the urine
sample [26, 27]. The blood alcohol level was quantified
by head-space GC analysis.
Case 2
The 23-year-old man was found dead at home, naked, and
his clothes were found near the body (as if he had just un-
dressed). The body was in a state of beginning putrefac-
tion and the cadaveric signs combined with the police in-
quiry revealed that the post-mortem interval was about 
3 days. The body weighed 56 kg and was 175 cm in length.
At autopsy, both lungs weighed 1,410 g and showed obvi-
ous congestion and oedema. Apart from congestion and
moderate putrefaction, the other organs showed no con-
spicuous anomalies. The heart and brain weighed 315 and
1,405 g, respectively. Microscopical examination confirmed
the general congestion and revealed signs of shock (such
as leucocyte sludging, micro-embolisms), mainly in the
sections of the heart, lungs, liver, kidneys and brain.
Eosinophilic cylinders were found in the renal tubuli, but
myoglobin staining was negative. In several brain regions,
apart from congestion and oedema, small—mainly peri-
vascular—bleedings were found. The medico-legal find-
ings were consistent with a disseminated intravascular co-
agulation (DIC) induced by hyperthermia.
Amphetamines and related compounds were screened
by routine methods such as GC-MS and HPLC-DAD, while
quantitative results were obtained by GC-MS and LC-MS.
Materials and methods
For both fatalities, since drug abuse was suspected, the standard
protocol used at our department was applied and appropriate sam-
pling for toxicological and histological examination was per-
formed. Small parts of the four brain lobes were sampled for drug
assay and for each lobe, cortex and medulla were isolated. There-
after, the brain was fixed in 4% buffered formaldehyde for 3–
4 weeks. On dissection, samples of various brain regions were
taken, followed by embedding in paraffin. Tissue sections were
prepared from the frontal, temporal, parietal and occipital regions,
the medulla oblongata, pons, cerebellar vermis, corpus callosum,
hippocampus, the basal ganglia (mammillary bodies, lentiform nu-
cleus, caudate nucleus and thalamus), the adjacent hypothalamus,
and the pituitary gland.
All similar samples in the control case 00/116 were taken as
blanks for drug assay and negative control tissue for immunohisto-
chemistry: a 28-year-old woman [post-mortem interval (PMI) of
48 h] was murdered by a shotgun through the heart and lungs. In a
few staining procedures, at random samples of five other control
cases were used. These were a 32-year-old female, murdered by
thoracic gunshot wounds (case number 00/8; PMI of 36 h), a 27-
year-old female, murdered by multiple stab wounds (case number
00/14; PMI of 56 h), a 26-year-old man, murdered by a gunshot
through the heart (case number 00/19; PMI of 42 h), a 17-year-old
man, who died due to polytrauma after a traffic accident (case
number 01/68, PMI of 91 h), and a 30-year-old female, murdered
by multiple stab wounds in thorax and neck (case number 01/181;
PMI of 58 h). In all control cases, extensive toxicological investi-
gations were negative.
Antibodies and immunostaining procedure
Monoclonal antibodies which specifically recognise MDMA and
MDA were kindly supplied by Microgenics Corp. (Fremont, Calif.):
they were purified from mouse ascites and available in two clones
(clones 1A9 and 5C2).
For the staining procedure, the Dako® Catalysed Signal Ampli-
fication (CSA) system, peroxidase (HRP) was used (supplied as a
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kit; Code K 1500). CSA is a very sensitive immunohistochemical
staining procedure incorporating a signal amplification method
based on the peroxidase catalysed deposition of a biotinylated phe-
nolic compound, followed by a secondary reaction with strepta-
vidin-peroxidase (User instructions, Dako® Catalysed Signal Am-
plification System). Sections were deparaffinised and rehydrated
according to standard protocols. After blocking endogenous biotin
and suppressing non-specific background staining as prescribed in
the procedure, the primary monoclonal mouse antibody was ap-
plied to the tissues and an incubation of 15 min followed. For the
primary antibodies, dilution series ranging from 1:20 to 1:5,000
were tested and the best results were obtained with dilutions be-
tween 1:150 and 1:500. The slides were then gently rinsed with
TBST buffer solution (Tris buffered saline with Tween 20) and
placed in a fresh TBST buffer bath 3 times for 3–5 min each. The
procedure was then continued by sequential 15 min incubations
with biotinylated link antibody, streptavidin-biotin complex, am-
plification reagent and streptavidin-peroxidase, respectively. The
staining was completed by a 3–5 min incubation with 3,3’-di-
aminobenzidine tetrahydrochloride (DAB) which is oxidised to a
brown-coloured precipitate by HRP. Hematoxylin counterstaining
was sometimes performed (e.g. in the pituitary gland in order to vi-
sualise the basophilic cells).
For the pituitary gland, a Periodic Acid Schiff (PAS)-orange 
G-staining on an immediately adjacent slide was performed in or-
der to discern the cell subtypes of the pituitary gland (acidophils,
basophils and chromophobes).
In all staining experiments of the two amphetamine fatalities, a
simultaneous incubation was performed with analogue sections
from control cases.
A positive control staining (recommended in the CSA kit) with
monoclonal mouse antibody to human B-cell (CD231) on formalin-
fixed and paraffin-embedded lymph node (from a patient with ma-
lignant B-cell lymphoma) and palatine tonsil tissue was performed.
At the same time, as an additional negative control, the staining pro-
cedure with the IgG1 fraction from normal mouse (provided in the
kit) and with the antibodies recognising MDMA and MDA on adja-
cent sections of the lymph node and palatine tonsil, was applied.
In order to test the specificity of the antibodies, we checked
whether it is possible to saturate the antibody binding sites with its
specific antigens and thus induce a negative immunodetection.
Therefore, either MDMA or MDA were added at various concen-
trations (dilution solution series from 10–12 g/ml to 1.5×10–3 g/ml)
to the antibody solution. This solution was placed on a rotary mix-
ing device during 24 h (at 4°C) prior to incubation of the slides.
The same procedure was performed using PMA (para -methoxy-
amphetamine) or AMP (amphetamine). For negative control incu-
bations, the antibody was replaced by IgG1 fraction from normal
mouse serum (supplied with the CSA kit) for each brain region. A
few random negative controls were performed in which phosphate
buffered saline (PBS) or bidistilled water (used to make the MDMA
or MDA solutions) were used instead of the primary antibody.
To exclude that MDMA or MDA added to the antibody solu-
tion and acting as a salt would prevent antigen-antibody binding,
an excess of MDMA or MDA was added to antibody solutions in
another immunodetection protocol. This concerned the immunode-
tection of two peroxisomal enzymes [catalase (CAT) and alanin-




An overview of the immunohistochemical results is pre-
sented in Table 1. Positive immunoreactions were ob-
tained in the neurons of all brain regions of both fatalities,
except for the corpus callosum due to the absence of neu-
ronal cell bodies at that particular site. A distinct positive
reaction was seen in all cortical regions of the brain lobes,
the neurons of the basal ganglia, and the cerebellar ver-
mis. Relatively weak staining of the neurons was found in
the brainstem. In addition, distinct reactivity was also ob-
served at the level of the white matter fibres in the slides
of the basal ganglia, the brainstem and corpus callosum in
both cases. A rather weak immunoreactivity of the white
matter in the cerebral lobes was noticed which is a dis-
crepancy with the results from chromatographic analysis
in the homogenates (see toxicological data).
Figures 1a, 1d, 2b and 3b show immunoreactive neu-
rons in the parietal and frontal region, the cerebellar ver-
mis and the hippocampus, respectively. The reaction pre-
sented as a mainly diffuse brownish cytoplasmic staining
of the perikaryon of the neurons. When the orientation of
the section plane was appropriate, staining of the axons
and dendrites was noticed. In particular, this was obvious
in the Purkinje cells presented in Fig. 2b where the course
of the dendrites to the molecular layer could be followed.
In addition, the granular layer cells of the cerebellar ver-
mis were positive, but at higher magnification, a hetero-
geneity in the staining pattern of these cells was observed
(see Fig. 2b). The cells of the dentate gyrus in the hip-
pocampus were also visualised (see Fig. 3c), however, the
heterogeneity was less pronounced. When comparing all
brain regions, differences in staining intensity and number
of positive neurons were seen, but these were not quanti-
fied.
In Fig. 4, a macroscopical overview of the immunore-
activity in the sections of the cerebellar vermis in Case 1
and in a control case is presented. The focal staining pat-
tern in the control differed from that in the case, as the
white matter was unreactive in the control and on micro-
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Table 1 Immunoreactions in neurons of various brain regions in
fatalities and control cases
Brain region Case 1 Case 2 Control 
(00/112) (01/34) cases
Neurons
Frontal lobe + + –
Parietal lobe + + –
Temporal lobe + + –
Occipital lobe + + –
Caudate nucleus + + –
Thalamus + + –
Lentiform nucleus + + –
Medulla oblongata ± ± –
Pons ± ± –
Vermis cerebelli + + –
Mammillary bodies + + –
Hypothalamus + + –
Hippocampus + + –





scopical examination, no immunoreactive neurons were
seen in the control.
Positive staining reactions were found for both antibody
clones; however, the staining aspect of both clones was
somewhat different. The two neuronal staining patterns are
presented in the parietal and frontal lobe (Fig. 1a and d, re-
spectively). When antibodies of the 5C2 clone were used,
the staining in the perikaryon was usually somewhat
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Fig. 1 a Immunohistochemical
staining of neurons (nerve cell
bodies, axons and dendrites) in
the parietal lobe of case 1.
b Staining of the parietal lobe
of case 1 after saturation of 
the antibody solution with
MDMA, and as a result, nega-
tive immunodetection was in-
duced. c Negative immunohis-
tochemical staining of the pari-
etal cortex in the control case.
(antibody clone 1A9; magnifi-
cation a 190×, b 140× and 
c 140× respectively). d Immu-
nohistochemical staining of
neurons (nerve cell bodies, 
axons and dendrites) in the
frontal lobe of case 1 (antibody
clone 5C2, magnification
190×)
Fig. 2 a Positive immuno-
staining of the cerebellar ver-
mis of case 2: the nerve cell
bodies, axons and dendrites of
the Purkinje cells are clearly
visible. The granular layer
cells can also obviously be dis-
cerned. In addition, staining at
the level of the white matter fi-
bres is seen (overview magnifi-
cation 95×). b Detail of the im-
munoreaction in the cerebellar
vermis of case 2 (magnifica-
tion 270×). c Negative immu-
nohistochemical staining of the
cerebellar vermis in a control
case. (For all pictures: stain-
ing using antibody clone 1A9)
flocky. Incubation with 1A9 rendered a more diffuse
colouring in the neuronal cytoplasm and the DAB precipi-
tate was more heterogenous. Variations in staining intensity
were also noticed when both clones were compared. Al-
though both clones distinctly revealed visualisation of the
cortical neurons, we further proceeded with 1A9 because
this antibody clone produced a crisp microscopical image.
The validation procedure for positive controls (as rec-
ommended in the kit), using anti-CD231 on formalin-
fixed and paraffin-embedded lymph node and palatine
tonsil tissue, was applied and found to be positive. The
same procedure with IgG1 fraction and with the antibodies
recognising MDMA and MDA on lymph node and tonsil
sections was negative.
In the control cases, no neurons were revealed, except
for a very faint diffuse cytoplasmic staining in the perikarya
(see Fig. 1c and Fig. 2c, parietal cortex and cerebellar ver-
mis, respectively).
Addition of pure MDMA or MDA to the antibody so-
lution in the high concentration of the series, totally abol-
ished the staining reaction or reduced staining to the back-
ground level as seen in the control cases (see Fig. 1b and
Fig. 4, parietal lobe and cerebellar vermis, respectively).
In the lower MDMA concentration range, a gradient in
the staining intensity was observed. These results point to
the specificity of the antibodies. Addition of PMA or am-
phetamine to the antibody solution was not able to induce
negative immunoreactivity. In addition, incubation with
mouse IgG1 fraction was negative in the case and control
tissues (data not shown).
The immunodetection of catalase and alanin/glyoxy-
late aminotransferase in the case and control liver was not
affected by addition of a similar amount of MDMA used
to saturate the MDMA antibody.
Figure 5 shows the results in the pituitary gland. Dis-
tinct immunoreactivity was observed in many cells, to-
gether with a prominent heterogeneity. As a result, differ-
ent types of staining intensity can be discerned: highly in-
tensely staining cells and abundant positive cells but also
some weakly stained and a few negative cells could be no-
ticed. Comparison of these results with the PAS-orange
G-staining in adjacent sections indicates that the strongly
stained cells correspond to the acidophils. The weakly
stained and negative cells are assumed to be the basophils
and chromophobes, respectively. The cells of the latter
subtype are indeed a minority.
Toxicological data
In Table 2, the MDMA, MDA, PMA and amphetamine
concentrations in femoral blood and homogenates of the
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Fig. 3 Staining of neurons in
the hippocampus of case 2 (an-
tibody clone 1A9). a Overview
(magnification 25×). b Detail
of the cortical neurons (magni-
fication 100×). c Detail of the
cells of the dentate gyrus
(magnification 100×)
Fig. 4 Macroscopical overview of the slides of the cerebellar ver-
mis (staining using antibody clone 1A9): left positive immuno-
staining in case 1, middle immunostaining in case 1 after saturation
of the antibody binding sites with MDMA inducing a negative re-
sult, right negative immunohistochemical staining of the cerebellar
vermis in a control case (00/116)
cortex and white matter of the four brain lobes are pre-
sented. The analysis revealed also an important level of
the drugs in the white matter.
In the first fatality, the routine analysis of blood and
urine disclosed the presence of a high level of ampheta-
mines (68.4 µg/ml in urine, immunoassay result) and trace
amounts of benzoylecgonine (0.7 mg/ml in urine, chro-
matographic result). Head-space GC analysis demon-
strated the absence of ethanol in blood and urine. In addi-
tion, the presence of MDMA in blood was demonstrated
by HPLC-DAD and GC-MS.
For the second case, apart from the data presented in
Table 2, no alcohol or other drugs were found.
Discussion
In this study, a method for immunohistochemical de-
tection of MDMA and MDA in human tissues is pre-
sented. In addition, we examined the distribution of
MDMA and MDA in various brain regions and the pitu-
itary gland.
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Table 2 Toxicological data 
in femoral blood, cortex and
medulla of the four brain lobes








Samples tested Case 1 (00/112) Case 2 (01/34)
MDMA MDA MDMA MDA PMA AMP
Femoral blood (µg/ml) 3.07 0.09 1.22 0.39 1.43 0.22
Brain region (µg/g)
Frontal lobe
Cortex 13.65 0.15 1.66 0.57 3.89 0.33
White matter 13.05 0.13 1.89 0.68 3.52 0.49
Temporal lobe
Cortex 15.42 0.16 1.62 0.81 3,25 0.43
White matter 13.53 0.21 3.00 0.81 4.40 0.44
Parietal lobe
Cortex 15.19 0.23 2.61 0.57 3.92 0.33
White matter 12.46 0.15 3.05 0.62 2.94 0.43
Occipital lobe
Cortex 15.98 0.18 1.87 0.52 3.23 0.33
White matter 10.87 0.19 3.30 0.57 4.74 0.32
Brainstem 13.18 0.22 1.95 0.76 3.20 0.35
Cerebellum 11.69 0.23 0.98 0.49 2.37 0.66
Fig. 5 a Overview of MDMA
immunoreactivity in the pitu-
itary gland (antibody clone
1A9; magnification 140×). 
b PAS Orange-G staining of
the immediately adjacent slide
visualising clearly the acid-
ophilic (orange colour) and 
basophilic cells (violet colour),
(magnification 140×). c Detail
of the staining reaction for
MDMA in the pituitary gland
(antibody clone 1A9; magnifi-
cation 300×). Following types
of staining can be discerned
(see arrows): 1, 2 obviously
positive cells showing variable
staining intensity (heterogene-
ity); the highly intensively
stained cells obscure the nu-
cleus (see arrow 1), 3 cells
having weak immunoreaction,
4 negative cells
Positive immunostaining for MDMA and MDA was
established in the neuron cell bodies, axons and dendrites
in various regions of the brain in two cases of fatal intox-
ication. However, the immunoreactivity was also present
at the level of the white matter fibres. The toxicological
data confirmed that substantial concentrations of MDMA
were present in the white matter. This is in accordance
with toxicological data obtained in methamphetamine
users [29]. The discrepancy between the substantial con-
centrations in the white and the grey matter, as detected
by GC-MS and LC-MS, and the relatively weak im-
munoreactivity of the white matter in the brain lobes, may
be explained by the fact that in the latter approach
MDMA can only be detected if it is bound to the tissue
and that this complex is not affected by the procedure of
fixation, paraffin embedding and sectioning. We presume
that unbound MDMA is washed out during the immuno-
histochemical preparation procedure. In the tissue homo-
genates used for the GC-MS and LC-MS analyses, both
the bound MDMA and the soluble form remain available
for detection. For methamphetamine as well, positive im-
munoreactivity in the cerebral cortex and in the white
matter was demonstrated [24]. In our study, topographic
differences in staining intensity were observed. In partic-
ular, distinct immunoreactivity was found in the neurons
of all cortical brain regions, the basal ganglia and the
cerebellum. However, the neuron cell bodies in the brain-
stem were relatively weakly stained and the white matter
fibres were more pronounced at that site. In addition, im-
munoreactivity was also found in the cells of the dentate
gyrus in the hippocampus and the granular layer cells of
the cerebellar vermis. This was not observed in the im-
munohistochemistry of morphine and methadone [13, 14].
The observed results in our two fatalities were well
consistent with the topographic data obtained in rats after
injection of [3H]-MDMA and [3H]-MDA [18]. We were
able to provide further information about the regional dis-
tribution of MDMA and MDA in human brain tissue. In
addition, the method may be used to further investigate
the biological effects, for example the interaction of
MDMA and MDA on serotonin systems which was previ-
ously demonstrated [18, 30], to study the influence on
memory [31] etc.
Immunostaining of the pituitary gland revealed a vari-
able reaction intensity in the different cells (acidophils,
basophils and chromophobes). The most intensely stained
cells were probably the acidophils as these are metaboli-
cally the most active cells. This is in accordance with the
MDMA-induced neuroendocrine effects such as increases
in plasma cortisol and prolactin levels which have been
documented in humans [32]. We will undertake studies to
correlate the heterogeneity of the MDMA reactivity with
the hormone producing cell types.
Although the mechanism of death in our two fatalities
was different, cardiopulmonary failure related to the sym-
paticomimetic effects of MDMA, and DIC due to hyper-
thermia, respectively and although there were obvious dif-
ferences in toxicology data, the immunoreactivity pattern
in the brain regions of both cases was fairly comparable.
Despite the hyperthermia and the post-mortem interval of
about 3 days in the second case leading to a more pro-
nounced tissue autolysis, the drugs could be immunohis-
tochemically demonstrated. However, it should be kept in
mind that interfering factors such as putrefaction may
give rise to false negative results. On the contrary, it can-
not be excluded that, theoretically, the putrefaction process
might lead to artefactual epitopes which are recognised
immunologically and thus could induce a false positive
reaction. However, in the control cases (with post-mortem
interval up to 2 days) no reaction was observed, except for
a background level.
In the cases and controls no immunoreactivity was
found after incubation with IgG1 fraction from normal
serum. In the controls a very faint diffuse staining was
found in a few neurons after incubation with the anti-
MDMA antibodies. Given the fact that saturation of the
antibody with pure MDMA abolished staining in the cases
and that in the controls, no amphetamines could be de-
tected by chromatographic analysis, the very weak diffuse
reaction in some neurons of the controls must be consid-
ered as the background level. A similar phenomenon of
diffuse staining in control neurons was experienced by
Wehner et al. [13, 14] in their study on immunodetection
of methadone and morphine in human brain. As empha-
sised by these authors, it must be kept in mind that the
CSA detection method yields an extreme amplification of
the primary signal (antigen-antibody complex) and that
also the slightest background becomes enhanced as a re-
sult of the sensitivity of the method.
Since saturation of the antibody with either MDMA or
MDA reduced staining to background level, the speci-
ficity of the antibodies and the method was confirmed.
According to the information obtained by the supplier, the
antibodies are highly specific for ecstasy (MDMA) and re-
lated compounds (MDA and MDEA) while cross-reaction
with amphetamine, methamphetamine and some medica-
tions (phentermine, phenyl propanolamine, pseudoephe-
drine) is always below 1% (pers. comm. Mr R. Ramage,
Microgenics Corp., Fremont, Calif.).
In summary, a reliable method for the specific immu-
nohistochemical detection of MDMA and MDA in human
brain tissues is presented. This method can be used as ev-
idence of intake or even poisoning with MDA, MDMA
and/or MDEA and can be a reliable alternative when the
usual samples (blood and urine) are not available for tox-
icological analysis, for example due to fulminant blood
loss in severely destroyed bodies, such as polytrauma in
train accident fatalities.
Further studies will be undertaken in order to investi-
gate whether this technique might be influenced by post-
mortem processes. In addition, MDMA immunodetection
might be used as a basis for further study of the distribu-
tion of these amphetamine analogues in the human body,
and thus be useful in the understanding of their biological
effects.
Acknowledgments The authors wish to thank Microgenics Corp,
Fremont, CA, USA and Mr R Ramage, PhD, Sr. Scientist in par-
ticular, for their advice and support and for providing the appro-
8
9priate antibodies. We also thank Mrs Thérèse De Vuyst for her as-
sistance in preparing the manuscript and Mr G. Van Limbergen for
technical assistance.
References
1. De Letter EA, Coopman VAE, Cordonnier JACM, Piette MHA
(2001) One fatal and seven non-fatal cases of 4-methylthioam-
phetamine (4-MTA) intoxication: clinico-pathological find-
ings. Int J Legal Med 114:352–356
2. Dowling GP, McDonough ET III, Bost RO (1987) ‘Eve’ and
‘Ecstasy’. A report of five deaths associated with the use of
MDEA and MDMA. JAMA 257:1615–1617
3. Rohrig TP, Prouty RW (1992) Tissue distribution of methy-
lenedioxymethamphetamine. J Anal Toxicol 16:52–53
4. Fineschi V, Masti A (1996) Fatal poisoning by MDMA (ec-
stasy) and MDEA: a case report. Int J Legal Med 108:272–275
5. De Letter EA, Clauwaert KM, Lambert WE, Van Bocxlaer JF,
De Leenheer AP, Piette MHA (2002) Distribution study of 3,4-
methylenedioxymethamphetamine and 3,4-methylenedioxyam-
phetamine (MDA) in a fatal overdose. J Anal Toxicol 26:113–
118
6. Decaestecker T, De Letter E, Clauwaert K, Bouche MP, Lam-
bert W, Van Bocxlaer J, Piette M, Van den Eeckhout E, Van
Peteghem C, De Leenheer A (2001) Fatal 4-MTA intoxication:
development of a liquid chromatographic-tandem mass spec-
trometric assay for multiple matrices. J Anal Toxicol 25:705–
710
7. Moriya F, Hashimoto Y (1999) Redistribution of basic drugs
into cardiac blood from surrounding tissues during early-stages
postmortem. J Forensic Sci 44:10–16
8. Hilberg T, Ripel Å, Slørdal L, Bjørneboe A, Mørland J (1999)
The extent of postmortem drug redistribution in a rat model. 
J Forensic Sci 44:956–962
9. De Letter EA, De Paepe P, Clauwaert KM, Belpaire FM, Lam-
bert WE, Van Bocxlaer JF, Piette MHA (2000) Is vitreous hu-
mour useful for the interpretation of 3,4-methylenedioxymeth-
amphetamine (MDMA) blood levels? Experimental approach
with rabbits. Int J Legal Med 114:29–35
10. Balkon J, Bidanset JH, Lynch VD (1980) Immunofluorescence
detection of drugs in postmortem tissues: a new technique with
potential for assessment of drug influence in cause of death. 
J Forensic Sci 25:88–94
11. Morley M, Gee DJ (1982) An assessment of the immunofluo-
rescence technique as a method for demonstrating the histolog-
ical localization of tetrahydrocannabinol in mammalian tissues.
J Forensic Sci 27:837–843
12. Ishiyama I, Mukaida M, Tanabe R, Kaiho M, Ueyama M
(1987) Histochemical demonstration of phenobarbital by im-
munocytochemistry. J Forensic Sci 32:1221–1234
13. Wehner F, Wehner H-D, Subke J, Meyermann R, Fritz P
(2000) Demonstration of morphine in ganglion cells of the hip-
pocampus from victims of heroin overdose by means of anti-
morphine antiserum. Int J Legal Med 113:117–120
14. Wehner F, Wehner H-D, Schieffer MC, Subke J (2000) Immu-
nohistochemical detection of methadone in the human brain.
Forensic Sci Int 112:11–16
15. Hood I, Mirchandani H, Monforte J, Stacer W (1986) Immu-
nohistochemical demonstration of homicidal insulin injection
site. Arch Pathol Lab Med 110:973–974
16. Lutz R, Pedal I, Wetzel C, Mattern R (1997) Insulin injection
sites: morphology and immunohistochemistry. Forensic Sci Int
90:93–101
17. Wehner F, Mittmeyer H-J, Wehner H-D, Schieffer MC (1998)
Insulin- or morphine-injection? Immunohistochemical contri-
bution to the elucidation of a case. Forensic Sci Int 95:241–246
18. Battaglia G, Zaczek R, Souza EB de (1990) MDMA effects in
brain: pharmacologic profile and evidence of neurotoxicity
from neurochemical and autoradiographic studies. In: Peroutka
SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxico-
logical effects of the drug MDMA. Kluwer Academic Publish-
ers, Boston, Dordrecht, London, pp 171–199
19. Feldman RS, Meyer JS, Quenzer LF (eds) (1997) Principles of
neuropsychopharmacology, Chapter 9. Serotonin. Sinauer As-
sociates, Inc Sunderland, Massachusetts, pp 358–359
20. Battaglia G, Sharkey J, Kuhar MJ, Souza EB de (1991) Neu-
roanatomic specificity and time course of alterations in rat
brain serotonergic pathways induced by MDMA (3,4-methy-
lenedioxymethamphetamine): assessment using quantitative au-
toradiography. Synapse 8:249–260
21. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999)
Cognitive performance in (±)3,4-methylenedioxymethamphet-
amine (MDMA, “Ecstasy”) users: a controlled study. Psycho-
pharmacology 143:417–425
22. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995)
Reorganization of ascending 5-HT axon projections in animals
previously exposed to the recreational drug (±)3,4-methylene-
dioxymethamphetamine (MDMA, “Ecstasy”). J Neurosci 15:
5476–5485
23. Fineschi V, Centini F, Mazzeo E, Turillazzi E (1999) Adam
(MDMA) and Eve (MDEA) misuse: an immunohistochemical
study on three fatal cases. Forensic Sci Int 104:65–74
24. Ishiyama I, Mukaida M, Yoshii T, Suyama H (1987) Histo-
chemical demonstration of methamphetamine by immunocyto-
chemistry. J Forensic Sci 32:658–672
25. Clauwaert KM, Van Bocxlaer JF, De Letter EA, Van Calen-
bergh S, Lambert WE, De Leenheer AP (2000) Determination
of the designer drugs 3,4-methylenedioxymethamphetamine,
3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxy-
amphetamine with HPLC and fluorescence detection in whole
blood, serum, vitreous humor, and urine. Clin Chem 46:1968–
1977
26. Clauwaert KM, Van Bocxlaer JF, Lambert WE, De Leenheer
AP (1996) Analysis of cocaine, benzoylecgonine, and cocaeth-
ylene in urine by HPLC with diode array detection. Anal Chem
68:3021–3028
27. Clauwaert KM, Van Bocxlaer JF, Lambert WE, De Leenheer
AP (1997) Liquid chromatographic determination of cocaine,
benzoylecgonine, and cocaethylene in whole blood and serum
samples with diode-array detection. J Chromatogr Sci 35:321–
328
28. Espeel M, Van Limbergen G (1995) Immunocytochemical lo-
calization of peroxisomal proteins in human liver and kidney. 
J Inherit Metab Dis 18 (S1):135–154
29. Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony
RM, Furukawa Y, Guttman M, Kish SJ (2001) Regional distri-
bution of methamphetamine in autopsied brain of chronic hu-
man methamphetamine users. Forensic Sci Int 116:163–169
30. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered
serotonin innervation patterns in the forebrain of monkeys
treated with (±)3,4-methylenedioxymethamphetamine seven
years previously: factors influencing abnormal recovery. J Neu-
rosci 19:5096–5107
31. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impair-
ment in abstinent MDMA (“Ecstasy”) users. Neurology 51:
1532–1537
32. Mas M, Farré M, Torre R de la, Roset PN, Ortuño J, Segura J,
Camí J (1999) Cardiovascular and neuroendocrine effects and
pharmacokinetics of 3,4-methylenedioxy-methamphetamine in
humans. J Pharmacol Exp Ther 290:136–145
